Results 21 to 30 of about 2,851,507 (299)

Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2022
Background: Cystic fibrosis is a rare, recessive, progressive genetic disease caused by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Yizi Wang, Bin Ma, Wenya Li, Peiwen Li
doaj   +1 more source

Is It Time for Quadruple Therapy to be First Line?

Canadian Journal of Gastroenterology, 2003
The most commonly used regimen for Helicobacter pylori therapy at present is twice-daily proton pump inhibitor (PPI)-based triple therapy. Bismuth-based therapy is the next most common treatment used by gastroenterologists.
Loren Laine
doaj   +1 more source

CURCUMIN IN COMBINATION WITH TRIPLE THERAPY REGIMES AMELIORATES OXIDATIVE STRESS AND HISTOPATHOLOGIC CHANGES IN CHRONIC GASTRITIS-ASSOCIATED HELICOBACTER PYLORI INFECTION

Arquivos de Gastroenterologia, 2017
BACKGROUND Helicobacter pylori (H. pylori) gastric infection is a main cause of inflammatory changes and gastric cancers. OBJECTIVE The aim of this study was finding the effects of curcumin on oxidative stress and histological changes in chronic ...
Arezu JUDAKI, Asghar RAHMANI, Jalil FEIZI, Khairollah ASADOLLAHI, Mohammad Reza HAFEZI AHMADI   +4 more
doaj   +1 more source

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection [PDF]

, 1998
In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection.
Miehlke, Stephan, Bolle, Karl-Heinz, Lehn, Norbert, Höchter, Wilhelm, Klann, Hermann, Krämer, Walter, Simon, Thomas, Stolte, Manfred, Meining, Alexander, Sommer, Albrecht, Bayerdörffer, Ekkehard, Weingart, Josef   +11 more
core   +1 more source

Triple F etableringsprojekt : Omvärldsanalys Policy

, 2020
Sverige har målsättningen att minska växthusgasutsläppen från inrikes transporter (exklusive flyg) med 70% till 2030 jämfört med 2010 samt att nå nettonollutsläpp av växthusgaser till atmosfären till 2045.
Vierth, Inge, Trosvik, Lina, Takman, Johanna   +2 more
core   +2 more sources

First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018
Background/Aims: The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70∼85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The
Moon Won Lee, Gwang Ha Kim, Sung Yong Han, Young Joo Park, Hye Kyung Jeon, Bong Eun Lee, Geun Am Song   +6 more
doaj   +1 more source

Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials

Respiratory Research, 2021
Background In some RCTs comparing triple therapy with dual therapy in COPD, there might be a bias resulting from the use of multiple inhaler devices. This meta-analysis included only RCTs that compared ICS/LABA/LAMA vs.
Huanyu Long, Hongxuan Xu, Jean-Paul Janssens, Yanfei Guo   +3 more
doaj   +1 more source

Triple inhaler therapy for COPD [PDF]

Thorax, 2015
The randomised controlled trial (GLISTEN) by Frith et al 1 showed significant improvements in trough FEV1, health-related quality of life and rescue medication when long-acting muscarinic antagonists (LAMA: as either tiotropium or glycopyrronium) were added to inhaled corticosteroid/long-acting beta-agonist (ICS/LABA: as fluticasone/salmeterol) in 773 ...
openaire   +2 more sources

Probiotics versus Rifaximin as Adjuvant Therapy for Helicobacter pylori Eradication [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases
Background and study aim: Helicobacter pylori infection, affecting over 50% of the global population, is a major cause of peptic ulcers and gastric cancer. Standard triple therapy (proton pump inhibitor [PPI], clarithromycin, amoxicillin) achieves modest
Bahaa Taha, Mohammed Ezz-Eldin, Tarek Abdelrahman   +2 more
doaj   +1 more source

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.

PLoS ONE, 2021
BackgroundAcute kidney injury (AKI) is an independent risk factor for mortality, which affects about 5% of hospitalized coronavirus disease-2019 (COVID-19) patients and up to 25-29% of severely ill COVID-19 patients.
Johanna Schneider, Bernd Jaenigen, Dirk Wagner, Siegbert Rieg, Daniel Hornuss, Paul M Biever, Winfried V Kern, Gerd Walz   +7 more
doaj   +1 more source